Copy
EuropaBio's Weekly Newsletter

View it in your browser

European bioeconomy in figures

A recent extensive macro-economic study, led by the Bio-based Industries Consortium (BIC), reveals that the European bioeconomy amounts a turnover of 2.1 trillion EUR and employment of 18.3 million jobs. “The Bio-based industry is already an important part of the European economy and a pivotal element in the transition towards a sustainable, circular economy in Europe with renewable raw materials as key enablers. Europe should continue on this path and create stable policies to further accelerate the European bioeconomy," says Marcel Wubbolts, Chair of the BIC. Read more

€23 million project to develop HIV vaccine

Financed by the European Commission, the European AIDS Vaccine Initiative (EAVI2020) brings together leading HIV researchers from public organisations and biotech companies from across the world in a focused effort to develop protective and therapeutic HIV vaccines. The EAVI2020 consortium unites scientists from 22 institutions, pooling their knowledge and expertise to develop novel candidate vaccines that can be taken through to human trials within five years. Read more

Agricultural biotech

What would happen if GM crops were no more? Higher food prices and a significant increase in greenhouse gas emissions would be some of the results of banning genetically modified organisms from the United States farm fields, according to a Purdue University study which examines the economic and environmental consequences triggered by such a hypothetical ban. Read more

Healthcare biotech

The European Medicines Agency (EMA) has published detailed guidance for pharmaceutical companies on the requirements to comply with its policy on the publication of clinical data. "The guidance will ensure that companies are aware of what is expected of them and are ready for the publication of these critical data", says Noël Wathion, EMA's Deputy Executive Director. Read more

Industrial biotech

According to a recent United Nations Conference on Trade and Development (UNCTAD) report, advanced and second generation biofuels have become a commercial reality in the context of advanced technologies, economic pressures and a political will to act on climate change. The report focuses on how the 2G biofuel market can be exploited in the wake of environmental commitments and how developing countries can be assisted. Read more
EuropaBio's 20 year anniversary: weekly spotlight on our members

Lilly has been serving patients in Europe since 1936, with 2016 marking our 80th year. Lilly pioneered medical breakthroughs like human insulin and the polio vaccine and seeks many other breakthrough therapies in areas such as Alzheimer’s, Oncology and Autoimmune diseases. We are passionate about building on our heritage in our continued quest to make life better for individuals and communities in Europe. Lilly is present with all elements of the pharmaceutical value chain in Europe, including research and development and a growing biotech manufacturing footprint. Today 9,000 of our approximate 41,000 worldwide employees work here in Europe, and of those, a majority are employed in R&D and manufacturing. Read more
Key dates to keep in mind
Follow us
Find us on Facebook
Visit our website
Say hello

Our mailing address is:
Avenue de l'Armée 6
B-1040 Brussels

Copyright © 2016 EuropaBio. All rights reserved.
unsubscribe from this list